Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch To Rituximab in MS
2010-023021-38Phase 2Completed
- Sponsor
- Region Västerbotten
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of rituximab in relapsing-remitting multiple sclerosis (RRMS) and multiple sclerosis (MS), sponsored by Region Västerbotten. Primary endpoints: Feasibility and safety of switching to rituximab and Health economic and cost-effectiveness outcomes. Started Nov 2010; status: completed.
02
Drugs
rituximab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)multiple sclerosis (MS)
Beyond the preview
Go deeper on 2010-023021-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023021-38.